The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
- Cavaletti, G.
- Cornblath, D. R.
- Merkies, I. S. J.
- Postma, T. J.
- Rossi, E.
- Frigeni, B.
- Alberti, P.
- Bruna, J.
- Velasco, R.
- Argyriou, A. A.
- Kalofonos, H. P.
- Psimaras, D.
- Ricard, D.
- Pace, A.
- Galie, E.
- Briani, C.
- Dalla Torre, C.
- Faber, C. G.
- Lalisang, R. I.
- Boogerd, W.
- Brandsma, D.
- Koeppen, S.
- Hense, J.
- Storey, D.
- Kerrigan, S.
- Schenone, A.
- Fabbri, S.
- Valsecchi, M. G.
DOIAbstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization ...
Add to ORKG